118708-61-5

Basic information

• Product Name: 4H-Pyran-4-one, 2-(hydroxymethyl)-5-[(4-methoxyphenyl)methoxy]-
• CAS NO: 118708-61-5
• Molecular Formula: C14H14O5
• Molecular Weight: 262.262
• Mol File: 118708-61-5.mol
• Article Data: 29

Chemical Properties

• CAS DataBase Reference: 4H-Pyran-4-one, 2-(hydroxymethyl)-5-[(4-methoxyphenyl)methoxy]-(CAS DataBase Reference)
• NIST Chemistry Reference: 4H-Pyran-4-one, 2-(hydroxymethyl)-5-[(4-methoxyphenyl)methoxy]-(118708-61-5)
• EPA Substance Registry System: 4H-Pyran-4-one, 2-(hydroxymethyl)-5-[(4-methoxyphenyl)methoxy]-(118708-61-5)

Safety Data

• Hazardous Substances Data: 118708-61-5(Hazardous Substances Data)

Usage

General Description

4H-Pyran-4-one, 2-(hydroxymethyl)-5-[(4-methoxyphenyl)methoxy]- is a chemical compound with the molecular formula C15H16O5. It is a derivative of pyran-4-one and contains a 2-(hydroxymethyl) group and a 5-[(4-methoxyphenyl)methoxy] group. 4H-Pyran-4-one, 2-(hydroxymethyl)-5-[(4-methoxyphenyl)methoxy]- has potential applications in the pharmaceutical industry, particularly in the development of new drugs for various therapeutic purposes. Its unique chemical structure makes it an interesting candidate for further research and development in drug discovery and medicinal chemistry.

Upstream product

• 824-94-2 p-methoxybenzyl chloride 
• 2746-25-0 p-Methoxybenzyl bromide 
• 501-30-4 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one 

Downstream Products

• 120404-75-3 1-hydroxy-2-hydroxymethyl-5-(4-methoxybenzyloxy)-4-pyridone 
• 722500-60-9 2-[(benzyloxy)methyl]-5-hydroxy-4H-pyran-4-one 
• 1443302-08-6 2-(ethoxymethyl)-5-(4-methoxybenzyloxy)-4H-pyran-4-one 
• 1443302-07-5 5-(4-methoxybenzyloxy)-2-(methoxymethyl)-4H-pyran-4-one 
• 135100-43-5 2-(ethoxymethyl)-5-hydroxy-4H-pyran-4-one 
• 1443302-43-9 5-(4-methoxybenzyloxy)-2-((pyrimidin-2-ylthio)methyl)-4H-pyran-4-one 
• 1443302-19-9 5-(4-methoxybenzyloxy)-2-((naphthalen-2-yloxy)methyl)-4H-pyran-4-one 
• 1443302-17-7 5-(4-methoxybenzyloxy)-2-((naphthalen-1-yloxy)methyl)-4H-pyran-4-one 
• 108352-97-2 5-((4-methoxybenzyl)oxy)-4-oxo-4H-pyran-2-carboxylic acid 
• 128109-26-2 5-p-Methoxybenzyloxy-2-chloromethyl-4-pyrone 
• 118679-90-6 2-(hydroxymethyl)-5-((4-methoxybenzyl)oxy)pyridin-4(1H)-one 
• 181647-86-9 2-Allyloxymethyl-5-(4-methoxy-benzyloxy)-1-methyl-1H-pyridin-4-one 
• 898045-04-0 C₂₈H₂₄O₈ 
• 898045-02-8 dimethyl (5-(4-methoxybenzyloxy)-4-oxo-4H-pyran-2-yl)methylphosphonate 

Relevant articles and documents

Investigation of Transfer Group, Tether Proximity, and Alkene Substitution for Intramolecular Silyloxypyrone-Based [5 + 2] Cycloadditions

Systematic investigation of intramolecular silyloxypyrone-based [5 + 2] cycloadditions revealed three significant factors impacting conversion to cycloadduct: (1) the silyl transfer group has a substantial influence on the rate of reaction, and the robust t-butyldiphenylsilyl group was found to be more effective overall than the conventional t-butyldimethylsilyl group; (2) α,β-unsaturated esters were generally more reactive than terminal olefins and afforded appreciable quantity of cycloadduct even at room temperature; and (3) the proximity of the tether to the silyl transfer group revealed a critical alignment trend between the pyrone and the alkene. Taken together, these investigations provided insight regarding the steric and electronic parameters that impact the scope and limitation of these reactions.

Synthesis and Evaluation of Bicyclic Hydroxypyridones as Inhibitors of Catechol O-Methyltransferase

A series of bicyclic pyridones were identified as potent inhibitors of catechol O-methyltransferase (COMT). Substituted benzyl groups attached to the basic nitrogen of the core scaffold gave the most potent inhibitors within this series. Rat pharmacokinetic studies showed medium to high levels of clearance for this series, but with high free fraction due to remarkably low levels of protein and tissue binding. In rat biomarker studies, levels of unbound drug exposure are seen in the brain, which exceed their respective IC50s, leading to changes in the levels of dopamine metabolites in a manner consistent with COMT inhibition.

D-AMINO ACID OXIDASE INHIBITORS AND THERAPEUTIC USES THEREOF

The present invention relates to compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: each of A, B, C, D, and E, independently, is C, N, N—H, O, S, or absent is a single bond or a double bond; each of X, Y, and Z, independentl